Ignite Creation Date:
2025-12-25 @ 2:52 AM
Ignite Modification Date:
2025-12-28 @ 8:55 PM
Study NCT ID:
NCT06028633
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-13
First Post:
2023-08-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
Sponsor:
Peking University First Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-22
First Submit QC Date:
None
Study First Post Date:
2023-09-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-10
Last Update Post Date:
2023-09-13
Last Update Post Date Type:
ACTUAL